


Tandem Concurrent Processes: One-Pot Single-Catalyst Biohydrogen Transfer for the Simultaneous Preparation of Enantiopure Secondary Alcohols

Fabrizio R. Bisogno,[†] Iván Lavandera,[†] Wolfgang Kroutil,[‡] and Vicente Gotor^{*†}

Departamento de Química Orgánica e Inorgánica, Instituto Universitario de Biotecnología de Asturias, University of Oviedo, 33006 Oviedo, Spain, and Department of Chemistry, Organic and Bioorganic Chemistry, University of Graz, Heinrichstrasse 28, 8010 Graz, Austria

vgs@fq.uniovi.es

Received October 27, 2008



A novel one-pot tandem biohydrogen transfer process to concurrently obtain two enantiopure *sec*-alcohols is presented; thus, using a suitable single enzyme and a catalytic amount of cofactor, several interesting building blocks could be easily achieved in an enantiocomplementary fashion, minimizing dramatically the quantity of reagents usually employed in the “coupled-substrate” approach.

Several (bio)catalytic methods to synthesize enantiopure secondary alcohols have been developed in the past few years to fulfill the increasing demand of this type of highly valuable compounds.¹ Among all methodologies described, stereoselective reduction of ketones² and enantioselective oxidation of racemic *sec*-alcohols³ using hydrogen transfer (HT) protocols have extensively been studied because of the mild and simple conditions employed in these transformations. In this context, biocatalyzed HT (also called “coupled-substrate” approach)


[†] University of Oviedo.

[‡] University of Graz.

(1) Breuer, M.; Ditrich, K.; Habicher, T.; Hauer, B.; Kessler, M.; Stürmer, R.; Zelinski, T. *Angew. Chem., Int. Ed.* **2004**, *43*, 788.

(2) Recent reviews: (a) Wu, X.; Xiao, J. *Chem. Commun.* **2007**, 2449. (b) Ikariya, T.; Blacker, A. J. *Acc. Chem. Res.* **2007**, *40*, 1300. (c) Gladiali, S.; Alberico, E. *Chem. Soc. Rev.* **2006**, *35*, 226. (d) Ikariya, T.; Murata, K.; Noyori, R. *Org. Biomol. Chem.* **2006**, *4*, 393.

SCHEME 1. Tandem ADH-Catalyzed Hydrogen Transfer Concept



employing alcohol dehydrogenases (ADHs) has recently gained increasing relevance.⁴ In these processes, a single enzyme reduces/oxidizes the target substrate, sacrificing a small molecule (cosubstrate) like 2-propanol/acetone as hydride donor/acceptor, used in a huge molar excess (at least 10 equiv compared to 1 equiv substrate to afford conversions higher than 90%) due to the reversible character of the reaction.

Very recently, it has been described that small activated ketones such as methyl acetoacetate⁵ or chloroacetone⁶ can be employed as cosubstrates in ADH-catalyzed oxidation of alcohols in near stoichiometric amount to achieve complete conversion. Herein, we present a system in which the sacrificial reaction has been turned into a highly valuable transformation, resulting in a *one-pot* process combining activated ketones with racemic *sec*-alcohols in order to concurrently obtain two different optically enriched alcohols catalyzed by a *single* enzyme, thus maximizing the *atom efficiency environmental factor E*⁷ of the process, since no additional reagent is discarded. Therefore, starting from a prochiral ketone and a racemic alcohol, we can obtain two optically pure alcohols (Scheme 1). Another advantage of this system is that the stereoselectivity can be tuned by simply changing the biocatalyst employed.

In a first set of experiments, we studied the influence of the ketone structure on some selected ADH-catalyzed reductions

(3) Recent bibliography: (a) *Modern Biooxidation. Enzymes, Reactions and Applications*; Schmid, R. D.; Urlacher, V. B., Eds.; Wiley-VCH: Weinheim, 2007. (b) Arends, I. W. C. E. *Catalytic Oxidations in Green Chemistry and Catalysis*; Sheldon, R. A.; Arends, I. W. C. E.; Hanefeld, U., Eds.; Wiley-VCH: Weinheim, 2007. (c) Lenoir, D. *Angew. Chem., Int. Ed.* **2006**, *45*, 3206. (d) *Modern Oxidation Methods*; Bäckvall, J.-E., Ed.; Wiley-VCH: Weinheim, 2004.

(4) Recent bibliography: (a) Buchholz, S.; Gröger, H. In *Biocatalysis in the Pharmaceutical and Biotechnology Industry*; Patel, R. N., Ed.; CRC Press: Boca Raton, 2007, p 757. (b) de Wildeman, S. M. A.; Sonke, T.; Schoemaker, H. E.; May, O. *Acc. Chem. Res.* **2007**, *40*, 1260. (c) Moore, J. C.; Pollard, D. J.; Kosjek, B.; Devine, P. N. *Acc. Chem. Res.* **2007**, *40*, 1412. (d) Goldberg, K.; Schroer, K.; Lütz, S.; Liese, A. *Appl. Microbiol. Biotechnol.* **2007**, *76*, 237. (e) Kroutil, W.; Mang, H.; Edegger, K.; Faber, K. *Adv. Synth. Catal.* **2004**, *346*, 125. (f) Kroutil, W.; Mang, H.; Edegger, K.; Faber, K. *Curr. Opin. Chem. Biol.* **2004**, *8*, 120. (g) Nakamura, K.; Matsuda, T. *J. Org. Chem.* **1998**, *63*, 8957.

(5) Peschko, C.; Stohrer, J. Enzyme catalyzed oxidation of secondary alcohols. Wacker Chemie AG, Germany, DE 102006009743, A1 20070906; CAN **2007**, *147*, 321414.

(6) Lavandera, I.; Kern, A.; Resch, V.; Ferreira-Silva, B.; Glieder, A.; Fabian, W. M. F.; de Wildeman, S.; Kroutil, W. *Org. Lett.* **2008**, *10*, 2155.

(7) (a) Sheldon, R. A. *Pure Appl. Chem.* **2000**, *72*, 1233. (b) Trost, B. M. *Science* **1991**, *254*, 1471.

TABLE 1. Tandem Concurrent Biohydrogen Transfer Using Activated Ketones and 2-Octanol^a

1a, R = *p*-H, X = Cl
1b, R = *p*-OH, X = Cl
1c, R = *p*-Me, X = Cl
1d, R = *p*-Cl, X = Cl
1e, R = *m,p*-Cl, X = Cl
1f, R = *m*-NO₂, X = Cl
1g, R = *p*-NO₂, X = Cl
1h, R = H, X = N₃
1i, R = H, X = CN

entry	ketone	enzyme	Prelog ADH			anti-Prelog ADH			
			2a–k		3a	2a–k		3a	
			conv ^b	ee (%) ^c	ee (%) ^c		conv ^b	ee (%) ^{c,d}	ee (%) ^c
1	1a	ADH-A	81	>99 (<i>R</i>) ^d	83 (<i>R</i>)	LB-ADH	90	>99 (<i>S</i>)	98 (<i>S</i>)
2	1b ^e	ADH-A	57	>99 (<i>R</i>) ^d	44 (<i>R</i>)	LB-ADH	83	>99 (<i>S</i>)	79 (<i>S</i>)
3	1c	ADH-A	97	>99 (<i>R</i>) ^d	94 (<i>R</i>)	LB-ADH	94	>99 (<i>S</i>)	92 (<i>S</i>)
4	1d	ADH-A	85	>99 (<i>R</i>) ^d	88 (<i>R</i>)	LB-ADH	86	>99 (<i>S</i>)	88 (<i>S</i>)
5	1e	ADH-A ^f	93	99 (<i>R</i>) ^d	98 (<i>R</i>)	PR2	90	99 (<i>S</i>)	>99 (<i>S</i>)
6	1f ^e	ADH-A	89	>99 (<i>R</i>) ^d	99 (<i>R</i>)	LB-ADH	90	>99 (<i>S</i>)	98 (<i>S</i>)
7	1g	ADH-A	91	>99 (<i>R</i>) ^d	>99 (<i>R</i>)	LB-ADH	90	>99 (<i>S</i>)	>99 (<i>S</i>)
8	1h ^e	ADH-T	73	>99 (<i>R</i>) ^d	70 (<i>R</i>)	PR2	84	>99 (<i>S</i>)	90 (<i>S</i>)
9	1i	ADH-T ^e	78	>99 (<i>S</i>)	72 (<i>R</i>)	g			
10	1j	ADH-A ^e	85	>99 (<i>R</i>) ^d	94 (<i>R</i>)	LB-ADH	87	>99 (<i>S</i>)	94 (<i>S</i>)
11	1k	ADH-T ^f	>99	>99 (<i>R</i>) ^d	>99 (<i>R</i>)	LB-ADH ^h	>99	>99 (<i>S</i>)	>99 (<i>S</i>)

^a Enzyme (3–5 U); [**1j**] 50 mM; [**3a**] 90–100 mM; [NAD(P)H] 1 mM. ^b Measured by achiral GC. ^c Measured by chiral GC or HPLC. ^d Switch in Cahn-Ingold-Prelog priority (CIP). ^e [**3a**] 45 mM. ^f [**3a**] 180 mM. ^g Not appropriate ADH found. ^h [**3a**] 400 mM.

using a low excess of the cosubstrate (2 equiv of 2-propanol; see Supporting Information). Thus, several ketones were reduced using a Prelog (ADH-A from *Rhodococcus ruber*)⁸ or an anti-Prelog [ADH from *Lactobacillus brevis* (LB-ADH)]⁹ enzyme. It could be observed that non-activated ketones like acetophenone afforded 50% conversion. When *para*-substituted acetophenones were reduced, electron-donating groups provided low conversions (<30%), while electron-withdrawing substituents afforded conversions of about 80%. Moreover, ketones with an electron-withdrawing group at the α -position such as α -chloroacetophenone furnished quantitative conversions. These results can be explained by the different oxidation–reduction potentials (ΔE°) between the ketone/alcohol pair with regards to the 2-propanol/acetone counterpart.¹⁰ It has been shown that α -halohydrins are stabilized via intramolecular H-bonding between the alcohol moiety and the halogen atom,¹¹ therefore preventing the ADH-catalyzed oxidation.⁶

Taking as an advantage the irreversibility of this HT, we tested the concept in a one-pot tandem protocol to simultaneously obtain two enantiopure *sec*-alcohols (see scheme of Table 1). In theory, an irreversible asymmetric reduction is required to achieve a complete kinetic oxidative resolution, and thus a molar amount of ketone to be reduced can be equal or slightly higher than the molar amount of alcohol to be oxidized. Thus, by mixing an activated ketone (1 equiv) with a racemic alcohol (1.8–2 equiv), the selective reduction of the prochiral compound plus the kinetic resolution of the racemate could be achieved via HT by a single enzyme and a catalytic amount of

the pyrimidinic cofactor that is internally recycled. As a result of the perfect selectivity shown by the biocatalysts utilized, the hydride is abstracted from a single enantiomer of the racemic alcohol and then exclusively transferred to one stereoface of the prochiral ketone.

Therefore, several α -chloro, α -azido, and α -cyano ketones (**1a–k**, Table 1) were purchased or synthesized and then combined with racemic 2-octanol (**3a**). Except for the cyano derivative **1i** (entry 9), we were able to find a suitable Prelog and anti-Prelog ADH to obtain enantioenriched or enantiopure (*R*)- or (*S*)-**3a** using activated aliphatic and (hetero)aryl ketones, which were reduced to the corresponding enantiopure alcohols with very high yields. Compounds with electron-donating groups in the phenyl ring (**1b**, entry 2) afforded lower conversions. By simply changing the enzyme, enantiocomplementary products could be achieved. Thus, ADH-A or LB-ADH were usually employed, but in some cases *Thermoanaerobacter* sp. ADH (ADH-T)¹² or PR2 provided better results. As an example, we scaled up the reaction of **2k** with LB-ADH up to a substrate concentration of 400 mM, showing the great robustness of the system. The obtained α -activated alcohols are important precursors of pharmaceutical compounds. For instance, (*S*)-**2a** is an intermediate for the synthesis of fluoxetine, tomoxetine, and nisoxetine,¹³ (*R*)-**2b** can be used as precursor of β -agonists like octopamine or denopamine,¹⁴ and optically active **2k** is a useful chiral building block for the synthesis of different pharmaceuticals.¹⁵

Several *sec*-alcohols were resolved using chloro ketone **1e** with ADH-A and **1k** with LB-ADH (Table 2). Thus, aromatic (**3b–d**), aliphatic (**3e–f**) such as sulcatol, or cycloalkyl (**3g**)

(8) This (*S*)-selective enzyme has a strong preference for NADH/NAD⁺. See: (a) Edegger, K.; Gruber, C. C.; Poessl, T. M.; Wallner, S. R.; Lavandera, I.; Faber, K.; Niehaus, F.; Eck, J.; Oehrlein, R.; Hafner, A.; Kroutil, W. *Chem. Commun.* **2006**, 2402. (b) Stampfer, W.; Kosjek, B.; Moitzi, C.; Kroutil, W.; Faber, K. *Angew. Chem., Int. Ed.* **2002**, *41*, 1014.

(9) This (*R*)-selective enzyme shows a preference for NADPH/NADP⁺. See, for instance: Wolberg, M.; Hummel, W.; Wandrey, C.; Müller, M. *Angew. Chem., Int. Ed.* **2000**, *39*, 4306.

(10) Eckstein, M. F.; Peters, M.; Lembrecht, J.; Spiess, A. C.; Greiner, L. *Adv. Synth. Catal.* **2006**, *348*, 1591.


(11) Goldstein, T.; Snow, M. S.; Howard, B. J. *J. Mol. Spectrosc.* **2006**, *236*, 1.

(12) Findrik, Z.; Vasić-Racki, D.; Lütz, S.; Daussmann, T.; Wandrey, C. *Biotechnol. Lett.* **2005**, *27*, 1087.

(13) Zhu, D.; Mukherjee, C.; Hua, L. *Tetrahedron: Asymmetry* **2005**, *16*, 3275.

(14) Lee, D.-M.; Lee, J.-C.; Jeong, N.; Lee, K.-I. *Tetrahedron: Asymmetry* **2007**, *18*, 2662.

(15) Kizaki, N.; Yasohara, Y.; Hasegawa, J.; Wada, M.; Kataoka, M.; Shimizu, S. *Appl. Microbiol. Technol.* **2001**, *55*, 590.

TABLE 2. Resolution of *sec*-Alcohols via ADH-Catalyzed Tandem HT Mediated by α -Chloro Ketones^a

alcohol	ADH-A		LB-ADH			
	conv ^b	ee (%) ^{c,d}	ee (%) ^c	conv ^b	ee (%) ^{c,d}	ee (%) ^c
3b	90	99 (R)	99 (R)	>99	>99 (S)	>99 (S)
3c	85	99 (R)	81 (R)	94	>99 (S)	87 (S)
3d	91	99 (R)	>99 (R)	99	>99 (S)	>99 (S)
3e	93	99 (R)	95 (R)	97	>99 (S)	96 (S)
3f	95	99 (R)	>99 (R)	>98	>99 (S)	>99 (S)
3g	94	99 (R)	98 (R)	>98	>99 (S)	>99 (S)

^a Enzyme (3–5 U); [1] 50 mM; [3a] 90–100 mM; [NAD(P)H] 1 mM. ^b Measured by achiral GC. ^c Measured by chiral GC. ^d Switch in CIP.

derivatives could be successfully obtained in enantioenriched form via tandem concurrent HT.

In summary, we have demonstrated a novel one-pot tandem system to simultaneously obtain two enantiopure *sec*-alcohols that possesses several advantages: conversion can be easily controlled by the amount of racemic alcohol added, a single biocatalyst and catalytic amount of cofactor are used, the selectivity can be tuned by choosing the appropriate enzyme, and the process can be scaled up.¹⁶ This is an elegant example that shows how biocatalysis can be applied for the “clean” synthesis of valuable enantiopure compounds maximizing the atom efficiency.⁷

Experimental Section

General. Alcohol dehydrogenases; ketones **1a**, **1d**, **1e**, **1i**, and **1k**; racemic alcohols **3a**, **3b**, **3c**, **3d**, **3e**, **3f**, and **3g**; and their corresponding ketones were purchased from commercial sources. α -Chloro ketones **1b**, **1c**, **1f**, **1g**, and **1j** were synthesized following modified protocols described in the literature.¹⁷ α -Azido ketone **1h** was obtained as published before.^{8a} Racemic alcohols **2a–k**

(16) The selection of the substrates was based on their different physical properties. Thus, ketones and aliphatic alcohols can be distilled, while the employed aromatic alcohols can be separated using *flash* chromatography.

were synthesized by conventional reduction from the corresponding ketones (NaBH₄, MeOH, room temperature). All other reagents and solvents were of the highest quality available. One unit (U) of ADH reduces 1.0 μM of acetophenone to 1-phenylethanol per minute at pH 7.5 and 30 °C in the presence of NAD(P)H. Flash chromatography was performed using silica gel 60 (230–400 mesh).

General Procedure for the Tandem Concurrent Biohydrogen Transfer Using Activated Ketones and 2-Octanol. In a 1.5 mL Eppendorf vial, 3–5 U of commercially available ADH (*Lactobacillus brevis* ADH, *Rhodococcus ruber* ADH-A, *Thermoanaerobacter* sp. ADH or PR2 ADH) in Tris-HCl buffer [50 mM, pH 7.5, 1 mM NAD(P)H, 1 mM MgCl₂ for LB-ADH] were mixed with both the racemic 2-octanol and the prochiral ketone (**1a–k**) in a 1.8–2:1 molar ratio respectively (e.g., 90–100 mM racemic **3a** and 50 mM ketone) in a final volume of 0.6 mL. The reaction was incubated at 30 °C with orbital rotation (150 rpm) for 24 h. Then, the reaction was stopped by extraction with ethyl acetate (2 \times 0.6 mL). The organic layer was separated by centrifugation (2 min, 13,000 rpm) and dried (Na₂SO₄). Conversions and enantiomeric excesses of the corresponding alcohols were determined by GC or HPLC analysis using an achiral or chiral stationary phase, respectively.

General Procedure for the Resolution of *sec*-Alcohols via ADH-Catalyzed Tandem HT Mediated by α -Chloro Ketones. In a 1.5 mL Eppendorf vial, 3–5 U of commercially available ADH (LB-ADH or ADH-A) in Tris-HCl buffer [50 mM, pH 7.5, 1 mM NAD(P)H, 1 mM MgCl₂ for LB-ADH] were mixed with both the racemic alcohol (**3b–g**, 90–100 mM) and the prochiral ketone (**1e** for ADH-A or **1k** for LB-ADH, 50 mM) in a final volume of 0.6 mL. The reaction was incubated at 30 °C with orbital rotation (150 rpm) for 24 h. Then, the reaction was stopped by extraction with ethyl acetate (2 \times 0.6 mL). The organic layer was separated by centrifugation (2 min, 13,000 rpm) and dried (Na₂SO₄). Conversions and enantiomeric excesses of the corresponding alcohols were determined by GC or HPLC analysis using an achiral or chiral stationary phase, respectively.

Acknowledgment. F.R.B. is supported by the Programme Al β n, the European Union Program of High Level Scholarships for Latin America (scholarship E07D402519AR). I.L. thanks Principado de Asturias for personal funding (Clarín Program). Financial support from the Spanish Ministerio de Ciencia e Innovación (MICINN, Project CTQ2007-61126/PPQ) is gratefully acknowledged.

Supporting Information Available: Experimental procedures and analytics are detailed. This material is free of charge via the Internet at <http://pubs.acs.org>.

JO802350F

(17) (a) Mei, Y.; Bentley, P. A.; Du, J. *Tetrahedron Lett.* **2008**, *49*, 3802. (b) Lee, J. C.; Bae, Y. H.; Chang, S. K. *Bull. Korean Chem. Soc.* **2003**, *24*, 407.